Dataset Information

Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status.

ABSTRACT:

Background

Appropriate patient selection is needed for targeted therapies that are efficacious only in patients with specific genetic alterations. We aimed to define subgroups of patients with candidate driver genes in patients with non-small cell lung cancer.

Methods

Patients with primary lung cancer who underwent clinical genetic tests at Guangdong General Hospital were enrolled. Driver genes were detected by sequencing, high-resolution melt analysis, qPCR, or multiple PCR and RACE methods.

Results

524 patients were enrolled in this study, and the differences in driver gene alterations among subgroups were analyzed based on histology and smoking status. In a subgroup of non-smokers with adenocarcinoma, EGFR was the most frequently altered gene, with a mutation rate of 49.8%, followed by EML4-ALK (9.3%), PTEN (9.1%), PIK3CA (5.2%), c-Met (4.8%), KRAS (4.5%), STK11 (2.7%), and BRAF (1.9%). The three most frequently altered genes in a subgroup of smokers with adenocarcinoma were EGFR (22.0%), STK11 (19.0%), and KRAS (12.0%). We only found EGFR (8.0%), c-Met (2.8%), and PIK3CA (2.6%) alterations in the non-smoker with squamous cell carcinoma (SCC) subgroup. PTEN (16.1%), STK11 (8.3%), and PIK3CA (7.2%) were the three most frequently enriched genes in smokers with SCC. DDR2 and FGFR2 only presented in smokers with SCC (4.4% and 2.2%, respectively). Among these four subgroups, the differences in EGFR, KRAS, and PTEN mutations were statistically significant.

Conclusion

The distinct features of driver gene alterations in different subgroups based on histology and smoking status were helpful in defining patients for future clinical trials that target these genes. This study also suggests that we may consider patients with infrequent alterations of driver genes as having rare or orphan diseases that should be managed with special molecularly targeted therapies.

SUBMITTER: An SJ

PROVIDER: S-EPMC3387024 | biostudies-literature | 2012

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status.

An She-Juan SJ Chen Zhi-Hong ZH Su Jian J Zhang Xu-Chao XC Zhong Wen-Zhao WZ Yang Jin-Ji JJ Zhou Qing Q Yang Xue-Ning XN Huang Ling L Guan Ji-Lin JL Nie Qiang Q Yan Hong-Hong HH Mok Tony S TS Wu Yi-Long YL

PloS one 20120629 6

<h4>Background</h4>Appropriate patient selection is needed for targeted therapies that are efficacious only in patients with specific genetic alterations. We aimed to define subgroups of patients with candidate driver genes in patients with non-small cell lung cancer.<h4>Methods</h4>Patients with primary lung cancer who underwent clinical genetic tests at Guangdong General Hospital were enrolled. Driver genes were detected by sequencing, high-resolution melt analysis, qPCR, or multiple PCR and R ...[more]

PMID: 22768234

Similar Datasets

Project description:BackgroundGenomic alterations in 8 genes are now the targets of FDA-approved therapeutics in non-small cell lung cancer (NSCLC), but their distribution according to genetic ancestry, sex, histology, and smoking is not well established.MethodsUsing multi-institutional genetic testing data from GENIE, we characterize the distribution of targetable genomic alterations in 8 genes among 8675 patients with NSCLC (discovery cohort: DFCI, N = 3115; validation cohort: Duke, Memorial Sloan Kettering Cancer Center, Vanderbilt, N = 5560). For the discovery cohort, we impute genetic ancestry from tumor-only sequencing and identify differences in the frequency of targetable alterations across ancestral groups, smoking pack-years, and histologic subtypes.ResultsWe identified variation in the prevalence of KRASG12C, sensitizing EGFR mutations, MET alterations, ALK, and ROS1 fusions according to the number of smoking pack-years. A novel method for computing continental (African, Asian, European) and Ashkenazi Jewish ancestries from panel sequencing enables quantitative analysis of the correlation between ancestry and mutation rates. This analysis identifies a correlation between Asian ancestry and EGFR mutations and an anti-correlation between Asian ancestry and KRASG12C mutation. It uncovers 2.7-fold enrichment for MET exon 14 skipping mutations and amplifications in patients of Ashkenazi Jewish ancestry. Among never/light smokers, targetable alterations in LUAD are significantly enriched in those with Asian (80%) versus African (49%) and European (55%) ancestry. Finally, we show that 5% of patients with squamous cell carcinoma (LUSC) and 17% of patients with large cell carcinoma (LCLC) harbor targetable alterations.ConclusionsAmong patients with NSCLC, there was significant variability in the prevalence of targetable genomic alterations according to genetic ancestry, histology, and smoking. Patients with LUSC and LCLC have 5% rates of targetable alterations supporting consideration for sequencing in those subtypes.

Project description:BackgroundMolecular testing for alterations in oncogenic driver genes and targeted therapies have become standard procedures for non-small cell lung cancer (NSCLC) patients. However, little evidence has shed light on the pattern of co-existence of driver genes in NSCLC, and whether they may have different tumor features affecting immunotherapy is still unclarified.MethodsGenomic alterations in 14 lung cancer-related genes were conducted in 3440 Chinese NSCLC patients using next-generation sequencing. Meanwhile, tumor mutational burden and immunotherapy dataset from the Memorial sloan kettering cancer center (MSKCC) and lung adenocarcinoma dataset from The Cancer Genome Atlas (TCGA) were utilized for analyzing the impact of the co-occurring alterations on patients' survival following immunotherapy.ResultsIn this cohort, 90.17% of patients had at least one somatic alteration in the 14 genes, including 51% of co-occurring alterations. TP53 and epidermal growth factor receptor (EGFR) were the most prevalent genes (54.74% and 53.55%, respectively), followed by KRAS, ERBB2, ALK, PIK3CA, ROS1, RET, MET, BRAF, KIT, FGFR1, PDGFRA, and NRAS. The prevalence of TP53, EGFR, and ERBB2 in our cohort were significantly higher than that from the TCGA database, whereas KRAS, BRAF, and PDGFRA were significantly lower than the latter. Furthermore, the patients who harbored multiple alterations (8.86%, 31/350) in eight driver genes survived longer and have a higher tumor mutation burden compared to the patients with a single alteration. Similar result was found between the patients with co-occurring alteration of EGFR and other driver genes and the patients with single EGFR alteration. Meanwhile, we found a distinct immune cell infiltration feature between patients with single and multiple driver gene alterations, as well as between patients with only EGFR alteration and co-occurring groups.ConclusionThis study identified a unique driver gene feature and found patients harboring co-occurring alterations of EGFR and other driver genes may benefit from immunotherapy, which may provide more therapeutic selections for EGFR-mutated NSCLC patients and merit additional investigation.

Project description:BackgroundLung cancer, one of the leading causes of cancer-related morbidity and mortality worldwide, is strongly associated with smoking as its primary carcinogenic factor. However, despite the strong link between smoking and lung cancer, not all smokers develop the disease, suggesting that individual genetic susceptibility and molecular mechanisms may play a critical role in the onset of lung cancer. Understanding the gene-driving mechanisms and immune regulatory pathways involved in smoking-related lung cancer remains one of the key challenges in current lung cancer research.MethodsThis study employs an integrative bioinformatics approach to explore gene expression differences and immune microenvironment characteristics between smokers with non-small cell lung cancer (NSCLC) and normal individuals. First, smoking-linked lung cancer driver genes (SLDCGs) were identified, followed by Mendelian Randomization (MR) and Summary-based Mendelian Randomization (SMR) analyses to further validate their causal relationships. Next, public databases, including TCGA, GEO, and GTEx, were used to systematically analyze the expression differences of SLDCGs across various clinical subgroups, and immune infiltration analysis was conducted to explore their potential roles in the immune microenvironment of NSCLC.ResultsThe study identified HLA-J and PRMT7 as core driver genes for smoking-associated NSCLC. MR analysis confirmed the potential causal relationship of HLA-J and PRMT7 in the development of NSCLC. Specifically, high expression of PRMT7 was closely associated with the occurrence of NSCLC, while low expression of HLA-J was implicated in immune evasion mechanisms in NSCLC. Additionally, immune microenvironment analysis revealed that HLA-J enhances the activity of immune cells, particularly T cells, to promote tumor immune recognition, whereas PRMT7 suppresses immune cell function, weakening immune surveillance and facilitating immune evasion.ConclusionThis study systematically reveals the molecular mechanisms of smoking-linked NSCLC through multidimensional bioinformatics analysis, highlighting the key roles of SLDCGs in immune evasion. The discovery of HLA-J and PRMT7 provides new theoretical foundations for targeted immunotherapy, with significant potential for early diagnosis and personalized treatment of smoking-induced NSCLC. Future research should focus on validating these genes in clinical samples and exploring their potential in immunotherapy.

Dataset Information

Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status.

Background

Methods

Results

Conclusion

Publications

Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets